Abstract:Cellular senescence describes an irreversible growth arrest characterized by distinct morphology, gene expression pattern, and secretory phenotype. The final or intermediate stages of senescence can be reached by different genetic mechanisms and in answer to different external and internal stresses. It has been maintained in the literature but never proven by clearcut experiments that the induction of senescence serves the evolutionary purpose of protecting the individual from development and growth of cancers. This hypothesis was recently scrutinized by new experiments and found to be partly true, but part of the gene activities now known to happen in senescence are also needed for cancer growth, leading to the view that senescence is a double-edged sword in cancer development. In current cancer therapy, cellular senescence is, on the one hand, intended to occur in tumor cells, as thereby the therapeutic outcome is improved, but might, on the other hand, also be induced unintentionally in non-tumor cells, causing inflammation, secondary tumors, and cancer relapse. Importantly, organismic aging leads to accumulation of senescent cells in tissues and organs of aged individuals. Senescent cells can occur transiently, e.g., during embryogenesis or during wound healing, with beneficial effects on tissue homeostasis and regeneration or accumulate chronically in tissues, which detrimentally affects the microenvironment by de- or transdifferentiation of senescent cells and their neighboring stromal cells, loss of tissue specific functionality, and induction of the senescence-associated secretory phenotype, an increased secretory profile consisting of pro-inflammatory and tissue remodeling factors. These factors shape their surroundings toward a pro-carcinogenic microenvironment, which fuels the development of aging-associated cancers together with the accumulation of mutations over time. We are presenting an overview of well-documented stress situations and signals, which induce senescence. Among them, oncogene-induced senescence and stress-induced premature senescence are prominent. New findings about the role of senescence in tumor biology are critically reviewed with respect to new suggestions for cancer therapy leveraging genetic and pharmacological methods to prevent senescence or to selectively kill senescent cells in tumors.

The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity

Cellular senescence: the good, the bad and the unknown

Immunosenescence: a key player in cancer development

Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

Role of immune cells in the removal of deleterious senescent cells

The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy

The senescence journey in cancer immunoediting

A silver bullet for ageing medicine?: clinical relevance of T-cell checkpoint receptors in normal human ageing

The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases

Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?

Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment

Cellular senescence impact on immune cell fate and function

Abstract 6592: Deciphering the effects of age on T cell immunity and immunotherapy

Senescence and cancer — role and therapeutic opportunities

Aging and Immune Function: Molecular Mechanisms to Interventions

Senescence as a therapeutic target in cancer and age-related diseases

The role of senescent T cells in immunopathology

T-cell immunity against senescence: potential role and perspectives

The Potent and Paradoxical Biology of Cellular Senescence in Cancer

Cellular senescence is a key mediator of lung aging and susceptibility to infection

Targeting Senescent Cells and Tumor Therapy (Review)